[Avoidance of excessive reliance on customs and constructive approaches in problem solving in public health nursing].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to H Mitsui.
Explore the source record for details and available documents.
Growth properties of malignantly transformed cell lines and their nontransformed counterparts were studied in the presence of a bacterial neutral protease (Dispase I). Among 10 transformed cell lines, 7 lines could proliferate in the presence of the protease in a floating state. Nontransformed cell lines and non-established cell strains failed to grow in this culture condition. The ability to grow in the presence of the protease was well correlated with their ability for anchorage-independent growth and tumorigenicity, and this provides a convenient primary test for evaluating cellular tumorigenicity.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
We have experienced six patients of juvenile ankylosing spondylitis. Their chief complaints were polyarthralgia or coxalgia, however, any pain or stiffness in lumbar regions was absent. These clinical features were atypical for those of ankylosing spondylitis, and much more like those of a peripheral arthropathy such as juvenile rheumatoid arthritis. After a long-term follow-up, all the patients showed definite clinical features of ankylosing spondylitis. HLA-B27 was found in 4 out of 6 cases. This frequency is almost equal to that of adult ankylosing spondylitis patients. HLA typing was very important in the early diagnosis.
HLA antigens were examined in 27 patients with juvenile rheumatoid arthritis. HLA-B27 was found in none. The result was different from most other previously reported studies. The most likely explanation for this difference is the possibility that some patients with juvenile ankylosing spondylitis may have been included among the patients in the other studies.
The mechanisms of glycerol-induced hemolysis and inhibition of the lysis by fructose were studied. Energy of activation, entropy of activation, and free energy of activation for the hemolytic process were calculated from the data on temperature change in the rate of hemolysis. The values of the thermodynamic quantities thus obtained indicated that the temperature change in the rate of hemolysis is brought about mainly by that in the viscosity of liquid. The presence of fructose in the hemolytic systems caused a reduction in both energy of activation and entropy of activation while free energy of activation remained almost unchanged. Pretreatment of erythrocytes with glycerol gave rise to complete hemolysis of the cells in hypotonic as well as hypertonic saline solutions. Thus, it appears that glycerol releases a portion of the lipids of the cell membrane into the surrounding medium and dehydrates the membrane, thereby promoting hemolysis. Fructose was considered to prevent dehydration of the membrane by glycerol.
Cytoplasmic membrane of Group A streptococcus has been obtained by treatment of the cells with a phage-associated lytic enzyme to dissolve the streptococcal cell wall, followed by shocking osmotically. The protoplast membrane fraction (PMF) remained as a distinct homogeneous structure in the electron micrograph and analysis showed a low rhamnose content. Febrile response produced by PMF was very slightly exhibited or not at all. PMF showed weak suppression against the growth of rat Yoshida sarcoma cells in culture and inhibition of [3H]-uridine incorporation into the sarcoma cells in vitro. In vivo antitumor experiments demonstrated that PMF has a mild inhibiting effect against mouse Ehrlich ascites carcinoma, though there was not observed a definite correlation between survival rate and dose level. Antitumor activity of PMF was thermo-labile and was strikingly abolished by treatment with a bacterial enzyme, Nagarse, but not so much by alpha-chymotrypsin.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.